Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab and Fianlimab in Japanese Patients With Advanced Malignancies
NCT03233139Phase 1Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2017
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of cemiplimab and fianlimab in malignant neoplasms (advanced stage) and non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events up to 136 weeks, Maximum Serum Concentration up to 136 weeks and 4 more. Started Jun 2017; status: active, not recruiting.
02
Drugs
cemiplimabfianlimab
03
Conditions
malignant neoplasms (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03233139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233139.